Aprea Therapeutics (APRE) investor Lytton discloses 3.2% ownership in 13G/A

Rhea-AI Filing Summary

Aprea Therapeutics, Inc. has an updated Schedule 13G/A reporting the holdings of Laurence W. Lytton. Lytton is disclosed as beneficially owning 390,807 shares of Aprea common stock, representing 3.2% of the class. This percentage is calculated using 12,382,776 shares outstanding as of May 13, 2026, as reported by the company for the quarter ended March 31, 2026.

Within this position, Lytton holds 322,220 shares with sole voting and dispositive power and 68,587 shares with shared voting and dispositive power. The filing reflects Amendment No. 1 and confirms his U.S. citizenship and contact details as the reporting person.

Key Figures

Beneficial ownership: 390,807 shares Percent of class: 3.2% Shares outstanding: 12,382,776 shares +2 more

5 metrics

Beneficial ownership 390,807 shares Total Aprea Therapeutics common shares beneficially owned by Laurence W. Lytton

Percent of class 3.2% Portion of Aprea Therapeutics common stock class beneficially owned by Lytton

Shares outstanding 12,382,776 shares Aprea common stock outstanding as of May 13, 2026 used for ownership calculation

Sole voting and dispositive power 322,220 shares Shares over which Lytton has sole power to vote and dispose

Shared voting and dispositive power 68,587 shares Shares over which Lytton has shared power to vote and dispose

Key Terms

Schedule 13G/A, beneficially owned, sole voting power, shared dispositive power

4 terms

Schedule 13G/A regulatory

"An updated Schedule 13G/A reporting the holdings of Laurence W. Lytton"

A Schedule 13G/A is an amended public filing with the U.S. securities regulator that updates a previous Schedule 13G, disclosing when an individual or group holds a substantial (typically over 5%) stake in a company and is claiming a passive, non‑controlling intent. Investors monitor these updates because rising or falling holdings can signal changing confidence, potential future moves, or shifts in voting power — like watching a public ledger where large shareholders quietly adjust their positions.

beneficially owned financial

"Lytton is disclosed as beneficially owning 390,807 shares of Aprea common stock"

Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.

sole voting power financial

"Lytton holds 322,220 shares with sole voting and dispositive power"

Sole voting power is the exclusive right to cast votes attached to a shareholder’s stock without needing approval from anyone else. Like holding the only remote control for a TV, it lets that holder decide corporate matters such as board members, mergers, and policy changes, making it important to investors because it concentrates control and can strongly influence a company’s strategy and the value of its shares.

shared dispositive power financial

"and 68,587 shares with shared voting and dispositive power"

FAQ

What percentage of Aprea Therapeutics (APRE) does Laurence W. Lytton report owning?

Laurence W. Lytton reports beneficial ownership of 3.2% of Aprea Therapeutics’ common stock. This is based on 390,807 shares he beneficially owns, compared with 12,382,776 shares outstanding as of May 13, 2026.

How many Aprea Therapeutics (APRE) shares does Laurence W. Lytton beneficially own?

Laurence W. Lytton beneficially owns 390,807 shares of Aprea Therapeutics common stock. This includes shares over which he has both sole and shared voting and dispositive power as detailed in the Schedule 13G/A filing.

What are Laurence W. Lytton’s sole and shared voting powers in Aprea Therapeutics (APRE)?

Laurence W. Lytton has sole voting power over 322,220 shares and shared voting power over 68,587 shares of Aprea Therapeutics common stock. These same share amounts apply to his sole and shared dispositive powers.

On what share count is the 3.2% ownership of Aprea Therapeutics (APRE) based?

The reported 3.2% ownership is calculated using 12,382,776 shares of Aprea Therapeutics common stock outstanding as of May 13, 2026, as disclosed in the company’s Form 10-Q for the quarter ended March 31, 2026.

What is the purpose of this Schedule 13G/A Amendment No. 1 for Aprea Therapeutics (APRE)?

This Schedule 13G/A Amendment No. 1 updates the beneficial ownership information of Laurence W. Lytton in Aprea Therapeutics. It restates his total holdings, percent of class, and the breakdown of sole and shared voting and dispositive powers.

When was Laurence W. Lytton’s Aprea Therapeutics (APRE) Schedule 13G/A signed?

The Schedule 13G/A was signed by Laurence W. Lytton as Reporting Person on August 13, 2026. The signature confirms the accuracy of the disclosed beneficial ownership information at the time of the filing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/13/2026 - 02:27 PM Accepted by SEC EDGAR 08/13/2026 - 02:27 PM Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 1)

Aprea Therapeutics, Inc.

(Name of Issuer)

Common Stock

(Title of Class of Securities)

03836J201

(CUSIP Number)

06/30/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 03836J201

1

Names of Reporting Persons

LYTTON LAURENCE W

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 322,220.00
6	Shared Voting Power 68,587.00
7	Sole Dispositive Power 322,220.00
8	Shared Dispositive Power 68,587.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

390,807.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

3.2 %

12

Type of Reporting Person (See Instructions)

IN

Comment for Type of Reporting Person: The percentage reported herein is calculated based on 12,382,776 shares of Common Stock outstanding as of May 13, 2026, as reported in the Form 10-Q filed by the issuer for the quarter ended March 31, 2026.

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Aprea Therapeutics, Inc.
(b)	Address of issuer's principal executive offices: 3805 Old Easton Road, Doylestown, PA 18902
Item 2.
(a)	Name of person filing: Laurence W. Lytton
(b)	Address or principal business office or, if none, residence: 467 CENTRAL PARK WEST, NEW YORK, NY 10025
(c)	Citizenship: United States
(d)	Title of class of securities: Common Stock
(e)	CUSIP No.: 03836J201
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 390,807
(b)	Percent of class: 3.2%
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 322,220
	(ii) Shared power to vote or to direct the vote: 68,587
	(iii) Sole power to dispose or to direct the disposition of: 322,220
	(iv) Shared power to dispose or to direct the disposition of: 68,587
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

LYTTON LAURENCE W

Signature:	/s/ Laurence W. Lytton
Name/Title:	Reporting Person
Date:	08/13/2026